VHL and nonpapillary renal cell carcinoma: For a long period, the main direction of ccRCC treatment is understanding mechanisms that VHL loss drives tumorigenesis, especially downstream of VHL-HIF pathway, including glutamine metabolic genes, mTOR signaling and lipid metabolism, among others [210].